Chronic lymphocytic leukemia (CLL): first-line treatment

Hematology Am Soc Hematol Educ Program. 2005:285-91. doi: 10.1182/asheducation-2005.1.285.

Abstract

For the past ten years, there has been a dynamic development of new therapeutic compounds and prognostic parameters for chronic lymphocytic leukemia (CLL). Hematologists and oncologists are challenged to use these new possibilities for an optimized, risk- and fitness-adapted treatment strategy, with the goal of achieving long-term remissions and preserving a good quality of life. This review is intended to summarize the current knowledge on first-line treatment of CLL.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia / epidemiology
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chromosome Aberrations
  • Chromosome Deletion
  • Chromosomes, Human, Pair 11
  • Chromosomes, Human, Pair 13
  • Chromosomes, Human, Pair 17
  • Humans
  • Immunotherapy / methods
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics
  • Leukemia, Lymphocytic, Chronic, B-Cell / pathology
  • Neoplasm Staging
  • Prognosis
  • Quality of Life
  • Rituximab
  • Thrombocytopenia / epidemiology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab